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Abstract: Background: The results of several studies have suggested that infections and sepsis, either
bacterial or viral, might be associated with elevated plasma proprotein convertase subtilisin/kexin
type 9 (PCSK9) levels. Since there are no data on PCSK9 levels and antibiotic resistance or the
severity of disease in patients with bacterial infections in intensive care units, the aim of this study
was to investigate whether any such associations exist. Methods: 100 patients (46 males, mean
age 67.12 ± 1.34 years) with bacterial infections who were staying in an intensive care unit (ICU)
longer than 48 h but less than 7 days and who were not receiving corticosteroids were analyzed.
Their serum levels of albumin, C-reactive protein, glucose, lactate, blood urea nitrogen, prothrombin
(international normalized ratio), total cholesterol, triglycerides, high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic
transaminase, PCSK9, and procalcitonin were measured. The severity of the patients’ condition
was assessed by using the Glasgow Coma Scale (GCS), the Sequential Organ Failure Assessment
(SOFA), and the Acute Physiology and Chronic Health Evaluation II (APACHE II) scales. Results:
Using a hierarchical regression modeling approach, no significant association was found between
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PCSK9 levels and either the severity of disease (APACHE II, SOFA, and GCS) indices or resistance to
antibiotics. Conclusion: The results suggest that there is no association between PCSK9 levels and
resistance to antibiotics or the condition of patients hospitalized in intensive care units.
Keywords: PCSK9; ICU; sepsis; antibiotic resistance
1. Introduction
Enzymes belonging to the proprotein convertase subtilisin/kexin (PCSKs) family are involved
in the pathophysiology of different diseases, such as atherosclerosis, viral and bacterial infections,
cancer, obesity, diabetes, Alzheimer’s disease, hypertension, arthritis, and even multiple trauma [1–5].
However, the most well-known action of one member of this family, PCSK9, in physiological conditions
is connected with its capability of regulating the surface expression of low-density lipoprotein receptors
(LDLRs) by targeting lysosomal degradation within hepatocytes, preventing LDLR recycling, and
thereby decreasing LDLR concentrations and the clearance of low-density lipoproteins (LDLs) but
also lipopolysaccharides (LPSes). On the basis of this, PCSK9 antibodies, more often called PCSK9
inhibitors, have been developed. They increase LDLR density on the surface of hepatocytes and
thereby significantly decrease the levels of elevated LDL cholesterol in circulation [6,7]. This is
particularly important in patients with very high levels of LDL cholesterol, such as those with familial
hypercholesterolemia, who due to lifelong elevated LDL cholesterol levels have an increased risk for
premature atherosclerotic cardiovascular disease [8–10].
Nevertheless, there have been a number of studies suggesting an association between increased
PCSK9 levels and infection and sepsis, either bacterial or viral, which can be attributed to the modulatory
effect of PCSK9 on the liver LDLR [11–16]. It seems that decreased clearance of pathogenic lipids, such
as LPS from Gram-negative bacteria and lipoteichoic acid (LTA) from Gram-positive bacteria, and
increased inflammatory cytokines occur due to the upregulation of PCSK9 expression, which might, at
least partially, explain the important role of PCSK9 in inflammation and sepsis. LPSes and LTA are key
lipid moieties of bacterial cell walls that stimulate the immune system.
It is well known that pathogenic lipids, such as endotoxins, are the trigger for the host inflammatory
response in sepsis [17]. They are incorporated into lipoprotein particles such as LDL, very-low-density
lipoprotein (VLDL), and HDL and are cleared from the blood by hepatocytes, which is a process
mediated by LDLR [18,19]. Since the clearance of pathogenic lipids during sepsis is similar to the
clearance of LDL particles, PCSK9 loss-of-function variants are associated with an increased clearance
of pathogen lipids, a decreased systemic inflammatory response, and decreased one-year mortality
from sepsis or in infection-related readmission after sepsis admission [20,21]. One study showed
better outcomes of septic shock in patients with lower PCSK9 levels [20]. A recent study on a cohort
of 10,922 patients hospitalized with infection showed that the risk of sepsis was not associated with
PCSK9 genetic variations [22]. On the other hand, some studies have confirmed that PCSK9 levels are
increased in septic patients, leading to decreased endotoxin clearance and increased rates of organ
failure [23]. However, there have been reports indicating decreased PCSK9 concentration in sepsis
and viral infections as well as PCSK9 inhibitors that have no effect on inflammation [14,24]. The
results of some experimental studies have also suggested that PCSK9 inhibition provides no protection
from LPS-induced mortality in mice [25]. Some experimental studies have also suggested that PCSK9
deficiency confers protection against systemic bacterial dissemination and inflammation, while PCSK9
overexpression exacerbates multiorgan pathology and proinflammatory states in early sepsis [26].
Since the results of studies on the association between serum concentrations of PCSK9 and
infection and sepsis have been contradictory and since there are no data on PCSK9 levels and antibiotic
resistance or the severity of disease of patients in intensive care units, the aim of this study was to
investigate whether any such associations exist.
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2. Methods
2.1. Patients
This cross-sectional study was performed in the general intensive care unit (ICU) of the Baqiyatallah
Hospital (Tehran, Iran). This study was approved by the ethics committee of the National Institute for
Medical Research Development, Tehran, Iran (code: IR.NIMAD.REC.1396.185), and written informed
consent was obtained from every participant or authorized relative in case of loss of consciousness.
One-hundred patients aged 18 to 80 with bacterial infections and who were staying in the ICU longer
than 48 h but less than 7 days whose data with all clinical details were available were enrolled in the
study (enrollment period: December 2017 to June 2018). The exclusion criteria were concomitant
participation in another study and receiving corticosteroids. Patients who were discharge or died in
less than 48 h or those who were included in another clinical study were excluded from this study.
2.2. Blood Sampling and Biochemical Measurements
Blood samples were collected from patients. Samples were centrifuged for 10 min at a speed of
1500–2000 rpm to separate the serum; to obtain plasma, blood samples (collected in tubes containing
anticoagulant) were centrifuged for 20 min at a speed of 2000 rpm at 4 ◦C. Serum and plasma
samples were kept at −70 ◦C until analyses. Serum levels of albumin (ALB), C-reactive protein (CRP),
glucose, lactate, blood urea nitrogen (BUN), potassium (K), sodium (Na), prothrombin (PT), partial
thromboplastin time (PTT), the international normalized ratio (INR), total cholesterol (TC), triglycerides
(TGs), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), and
the erythrocyte sedimentation rate (ESR) were measured in all patients using routine enzymatic assays
and commercial kits. PCSK9 and procalcitonin (PCT) levels were measured by an ELISA according to
the manufacturer’s instructions.
2.3. Assessment of the Severity of Disease
Level of consciousness was monitored using the GCS (Glasgow Coma Scale). A SOFA (Sequential
Organ Failure Assessment) score was used to determine the status of multiple organs, such as
coagulation and the cardiovascular system, respiratory system, nervous systems, liver, and kidneys.
An Acute Physiology and Chronic Health Evaluation II (APACHE II) scale was used to assess the
severity of the patients’ condition.
2.4. Statistical Analyses
Statistical analyses were performed using Statistical Package Social Sciences (SPSS) software for
Microsoft Windows (SPSS 17.0, SPSS Inc., and Chicago, IL, USA) and STATA 15 (StataCorp, College
Station, Texas, USA). Descriptive statistics were calculated for all patients. The chi-square test was used
to statistically analyze the categorical variables. Using the Kolmogorov–Smirnov test, data were tested
for a normal distribution. Variables with a normal distribution are presented as the mean and standard
error, and nonparametric data are presented as the median and interquartile (IQR). A three-step
hierarchical regression model was used for each outcome measure. In the first step (unadjusted model),
the serum PCSK9 concentration was entered as the main predictor; in the next step (minimally adjusted
model), demographic variables including age, gender, body weight, smoking, and diabetes were added
to the previous model; and finally, in the third step, biochemical measures including fasting blood
sugar (FBS), high-sensitivity CRP (hsCRP), lactate, BUN ALB, TG, TC, HDL-C, LDL-C, PCT, PT, PTT,
SGPT, SGOT, ESR, K, and Na were further added to the aforementioned model (fully adjusted model).
The change in the models at each step was assessed by partial F-tests, and the amount of change in the
model predictability was measured by an R2 index. Additionally, to assess the moderating effect of the
above-mentioned variables (in steps 2 and 3) with PCSK9, a regression model including the main and
interaction effects was constructed for each outcome measure. A backward elimination strategy with a
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free structure was also employed (exploratory) to find the possible predictors of the outcomes. Scatter
plots between the disease severity outcomes and PCSK9 were generated to assess the presence of any
nonlinear association. Here, p-values < 0.05 were considered statistically significant.
3. Results
One-hundred patients were included in the study: 46 males and 54 females with a mean age
of 67.12 ± 1.34. Twenty-two percent of patients had diabetes, and 39% were smokers. Their mean
CRP level was 11.84 ± 0.41 mg/dL, and about 67% of patients had a CRP value above 10 mg/dL.
Gram-negative bacteria were isolated from 97% of patients, and among them Klebsiella sp., Pseudomonas
aeruginosa, and Acinetobacter were the most frequent. About 70% of patients were resistant to four
antibiotics (Ceftriaxone > Ciprofloxacin > Meropenem > Amikacin). Details of the patients’ data are
shown in Tables 1 and 2.
Table 1. Characteristics of the patients.
All Samples (n = 100)
Age (y) 67.12 ± 1.34
Gender (%)
Female 54
Male 46
Weight (kg) 78.82 ± 1.12
Height (cm) 162.32 ± 1.5
Smoker (%) 39
Diabetes (%) 22
FBS (mg/dL) 171.46 ± 6.43
CRP (mg/dL) 11.84 ± 0.41
Lac (mmol/L) 2 (2–4)
BUN (mg/dL) 21 (17–31.75)
ALB (g/dL) 2.9 ± 0.1
TG (mg/dL) 291.5 ± 10.14
TC (mg/dL) 179.1 ± 5.8
HDL-C (mg/dL) 34 (32–45)
LDL-C (mg/dL) 165.5 (136–192)
PCT (ng/mL) 1.6 (0.98–2.3)
PT (s) 16 (13–19)
PTT (s) 27.3 ± 0.9
INR (s) 1.4 (1.2–2)
SGPT (U/L) 23 (21–32)
SGOT (U/L) 32 (23–43)
ESR (mm/hr) 17 (15–24)
K (mEq/L) 4.31 ± 0.1
Na (mEq/L) 138.81 ± 0.82
PCSK9 (ng/mL) 98.85 (89.15–123)
APACHE II score 22 (17–24)
SOFA score 8.35 ± 0.41
GCS score 7 (6–10)
ALB: albumin; APACHE: Acute Physiology and Chronic Health Evaluation; BUN: blood urea nitrogen; CRP:
C-reactive protein; ESR: erythrocyte sedimentation rate; FBS: fasting blood sugar; GCS: Glasgow Coma Scale;
HDL-C: high-density lipoprotein cholesterol; INR: international normalized ratio; K: potassium; kg: kilogram;
Lac: lactate; LDL-C: low-density lipoprotein cholesterol; ml: milliliter; Na: sodium; PCSK9: proprotein convertase
subtilisin/kexin type 9; PCT: procalcitonin; pg: picogram; PT: prothrombin time; PTT: partial thromboplastin time;
S: seconds; SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic pyruvic transaminase; SOFA:
Sequential Organ Failure Assessment; TC: total cholesterol; TG: triglyceride; Y: years; values are expressed as mean
± standard error (SE) or median (interquartile (IQR)).
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Table 2. Types of isolated organisms and antibiotic resistance in the patients.
All Samples (n = 100)
Gram-negative bacteria (%)
Klebsiella sp. 35
Pseudomonas aeruginosa 23
Acinetobacter 35
Pseudomonas sp. 1
Escherichia coli 3
Gram-positive bacteria (%) Staphylococcus aureus 1
Enterococcus 2
Type of antibiotic resistance (%)
Meropenem 82
Vancomycin 2
Amikacin 74
Ciprofloxacin 83
Ceftriaxone 86
Antibiotic resistance (%)
Sensitive 9
Resistance to one antibiotic 3
Resistance to two antibiotics 9
Resistance to three antibiotics 10
Resistance to four antibiotics 69
The results of hierarchical regression modeling indicated that there was no association between
PCSK9 levels and APACHE II and GCS in the first, second, and third steps of hierarchical modeling.
However, in the first and second steps of hierarchical modeling, significant associations were observed
between PCSK9 levels and SOFA, but after adjusting for biochemical measures for the association in
the third step, the association did not remain statistically significant (p = 0.027) (Table 3). In the same
manner, there was no association between serum PCSK9 levels and antibiotic resistance either in the
unadjusted or adjusted models (Table 3).
Table 3. Hierarchical regression modeling exploring the association between serum PCSK9
concentrations and the severity of disease indices.
Outcome Measure Model Coefficient 95% CI SE p−Value
APACHE II score
Model 1 −0.04 −0.12, 0.05 0.04 0.372
Model 2 −0.05 −0.14, 0.04 0.04 0.261
Model 3 −0.08 −0.20, 0.03 0.06 0.150
SOFA score
Model 1 −0.06 −0.11, −0.01 0.02 0.012
Model 2 −0.07 −0.12, −0.02 0.03 0.010
Model 3 −0.03 −0.10, 0.03 0.03 0.278
GCS score
Model 1 0.01 −0.04, 0.06 0.03 0.681
Model 2 0.02 −0.04, 0.07 0.03 0.492
Model 3 0.01 −0.05, 0.08 0.03 0.674
Antibiotic resistance
Model 1 1.03 1.00, 1.06 0.01 0.089
Model 2 1.02 0.99, 1.06 0.02 0.162
Model 3 1.03 0.96, 1.12 0.04 0.377
Model 1: unadjusted model; Model 2: minimally adjusted model for demographic variables including age, gender,
body weight, smoking, and diabetes; Model 3: fully adjusted model for demographic variables plus biochemical
measures including FBS, hsCRP, lactate, BUN ALB, TG, TC, HDL-C, LDL-C, PCT, PT, PTT, SGPT, SGOT, ESR, K, and
Na. CI: confidence interval; SE: standard error.
We also used a backward elimination strategy with a free structure to exploratorily find the
possible predictors of the outcomes. The results confirmed the above results, suggesting no association
between PCSK9 levels and APACHE II (coefficient: −0.06; SE: 0.04; 95% confidence interval (CI): −0.01,
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0.02; p = 0.135), SOFA (coefficient: −0.04; SE: 0.02; 95% CI: −0.09, 0.01; p = 0.099), and GCS (coefficient:
0.002; SE: 0.02; 95% CI: −0.05, 0.05; p = 0.926).
We also assessed the nonlinear association (interaction) between PCSK9 levels and demographic
and biochemical measures. Scatter plots of outcomes (APACHE, GCS, and SOFA) versus serum PCSK9
concentrations did not show any evidence of nonlinearity (Figure 1).
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4. Discussion
This is the first study investigating whether there is an association between serum PCSK9 levels
and resistance to antibiotics as well as the severity of disease in patients in intensive care units. The
results of this study show that there was no significant association between PCSK9 levels and resistance
to antibiotics or any other parameters of the severity of a patient’s condition.
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It has been suggested that increased circulating PCSK9 might be associated with different bacterial
and viral infections and that inhibiting the activity of circulating PCSK9 levels using PCSK9 inhibitors
may be useful for the treatment of bacterial sepsis and septic shock [27]. Some authors have found that
plasma PCSK9 at normal levels has no influence upon hepatocyte bacterial endotoxin clearance, but
as levels rise, there is a progressive inhibition of clearance: during sepsis, PCSK9 levels are greatly
increased and highly correlated with the development of subsequent multiple organ failure [23]. The
presence of multiple PCSK9 loss-of-function alleles seems to decrease the risk of one-year death or
infection-related readmission in sepsis survivors [21]. According to the results of some other studies,
PCSK9 loss-of-function variants are not associated with an increased risk of hospitalization for a
serious infection or with the odds of sepsis in patients hospitalized with serious infections [28]. Some
authors have shown that plasma PCSK9 levels are elevated equally in patients with gram-positive or
gram-negative bacterial infections but that particularly high levels are seen in patients with Streptococcus
pneumoniae bacteremia; further, a reduced plasma PCSK9 response in patients with bacteremia is
associated with increased mortality [29]. The results of some studies have indicated that inhibiting
PCSK9 function may be an effective treatment option for both gram-positive and gram-negative
sepsis [30]. According to our results, despite all these quite convincing data indicating that serious
infections and sepsis might be associated with elevated plasma PCSK9 levels, it seems that there is no
association between PCSK9 levels and resistance to antibiotics or the condition of patients hospitalized
in intensive care units.
Our study had some limitations. The number of patients was relatively small. Therefore, the
results should be considered a pilot. Another limitation might be that the patients in the ICU had
different diseases, which maybe could influence PCSK9 values. An important limitation is that patients
with similar conditions and diseases should be enrolled to avoid possible bias. However, this would
require many more patients and a larger study, which we intend to perform in the near future. One
more limitation is that the study population was relatively severe according to the high prevalence of
resistant strains, low albumin level, high SOFA scores, and high incidence of bacteremia. In the larger
study we are planning we will perform a stratified/subgroup analysis accordingly.
5. Conclusions
There is a significant amount of convincing data indicating that serious infections and sepsis
might be associated with elevated plasma PCSK9 levels. Therefore, it was interesting to investigate
whether there is an association between serum PCSK9 levels and resistance to antibiotics as well as the
severity of disease of patients in intensive care units. Our results suggest that there is no association
between PCSK9 levels and resistance to antibiotics or the condition of patients hospitalized in intensive
care units.
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